Morissette Pierre, Hreiche Raymond, Mallet Louise, Vo Dean, Knaus Edward E, Turgeon Jacques
Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.
J Psychopharmacol. 2007 Sep;21(7):735-41. doi: 10.1177/0269881106072669. Epub 2006 Nov 8.
Prolongation of the QT interval has been observed during treatment with olanzapine, a thienobenzodiazepine antipsychotic agent. Our objectives were 1) to characterize the effects of olanzapine on cardiac repolarization and 2) to evaluate effects of olanzapine on the major time-dependent outward potassium current involved in cardiac repolarization, namely I(Kr) (I(Kr): rapid component of the delayed rectifier potassium current).Isolated, buffer-perfused guinea pig hearts (n = 40) were stimulated at different pacing cycle lengths (150-250 msec) and exposed to olanzapine at concentrations ranging from 1 to 100 microM. Olanzapine increased monophasic action potential duration measured at 90% repolarization (MAPD90) in a concentration-dependent manner by 6.7 +/- 0.7 msec at 3 microM but by 26.0 +/- 4.3 msec at 100 microM (250 msec cycle length). Increase in MAPD(90) was also reverse frequency dependent; 30 microM olanzapine increased MAPD90 by 28.0 +/- 6.2 msec at a pacing cycle length of 250 msec but by only 18.9 +/- 2.2 msec at a pacing cycle length of 150 msec. Experiments in HERG-transfected (HERG: human ether-a-gogo-related gene) HEK293 cells (n = 36) demonstrated concentration-dependent block of the rapid component (I(Kr)) of the delayed rectifier potassium current: tail current was decreased 50% at olanzapine 3.8 microM. Olanzapine possesses direct cardiac electrophysiological effects similar to those of class III anti-arrhythmic drugs. These effects were observed at concentrations that can be measured in patients under conditions of impaired drug elimination such as renal or hepatic insufficiency, during co-administration of other CYP1A2 substrates/inhibitors or after drug overdose. These results offer a new potential explanation for QT prolonging effects observed during olanzapine treatment in patients.
在使用噻吨苯二氮䓬类抗精神病药物奥氮平治疗期间,观察到QT间期延长。我们的目标是:1)描述奥氮平对心脏复极化的影响;2)评估奥氮平对参与心脏复极化的主要时间依赖性外向钾电流,即I(Kr)(I(Kr):延迟整流钾电流的快速成分)的影响。
将分离的、用缓冲液灌注的豚鼠心脏(n = 40)以不同的起搏周期长度(150 - 250毫秒)进行刺激,并暴露于浓度范围为1至100微摩尔的奥氮平中。奥氮平以浓度依赖性方式增加在90%复极化时测量的单相动作电位持续时间(MAPD90),在3微摩尔时增加6.7±0.7毫秒,但在100微摩尔时(250毫秒周期长度)增加26.0±4.3毫秒。MAPD(90)的增加也是反向频率依赖性的;30微摩尔奥氮平在250毫秒起搏周期长度时使MAPD90增加28.0±6.2毫秒,但在150毫秒起搏周期长度时仅增加18.9±2.2毫秒。在转染了人类ether-a-gogo相关基因(HERG)的HEK293细胞(n = 36)中进行的实验表明,奥氮平对延迟整流钾电流的快速成分(I(Kr))具有浓度依赖性阻断作用:在3.8微摩尔奥氮平作用下,尾电流降低50%。奥氮平具有与III类抗心律失常药物相似的直接心脏电生理作用。在药物消除受损的患者(如肾功能或肝功能不全患者)、在同时使用其他CYP1A2底物/抑制剂或药物过量后可测量到的浓度下观察到了这些作用。这些结果为在奥氮平治疗患者期间观察到的QT延长效应提供了一个新的潜在解释。